A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable… (NCT05320692) | Clinical Trial Compass
Active — Not RecruitingPhase 3
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
China423 participantsStarted 2022-08-09
Plain-language summary
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Voluntarily participate in this study and sign informed consent.
✓. Subjects diagnosed with HCC or clinically diagnosed with HCC by histopathology / cytology.
✓. Baseline imaging examination has at least one measurable lesion.
✓. Child-Pugh liver function rating was Grade A Within 7 days before randomization.
✓. ECOG PS score within 7 days before randomization: 0 or 1. Other protocol defined inclusion criteria could apply.
Exclusion criteria
✕. Known hepatocholangiocarcinoma, sarcomatoid hepatocellular carcinoma, mixed cell carcinoma and lamellar cell carcinoma.
✕. Subjects who are ready for or have previously received organ or allogeneic bone marrow transplantation.
✕. Has any active autoimmune disease or a history of autoimmune disease and may relapse.
✕. Suffering from hypertension and can not be well controlled by antihypertensive drugs.
✕. With clinical symptoms or diseases of the heart that are not well controlled.
✕. Previous or current central nervous system metastasis.
✕. The subject has congenital or acquired immune deficiency (such as HIV infection).